WASHINGTON (Reuters) - Shire PLC subsidiaries will pay $350 million to settle U.S. federal and state False Claims Act allegations related to unlawful methods to push “Dermagraft,” a treatment for diabetic foot ulcers, the U.S. Justice Department said in a statement on Wednesday.
"The settlement resolves allegations that Dermagraft salespersons unlawfully induced clinics and physicians with lavish dinners, drinks, entertainment and travel; medical equipment and supplies; unwarranted payments for purported speaking engagements and bogus case studies; and cash, credits and rebates, to induce the use of Dermagraft," it said.
(Reporting by Washington Newsroom; Editing by Chizu Nomiyama)
| 1st Jan change | Capi. | |
|---|---|---|
| +63.05% | 854B | |
| +39.42% | 636B | |
| -4.78% | 361B | |
| +17.52% | 324B | |
| +8.43% | 301B | |
| +14.19% | 247B | |
| +5.81% | 230B | |
| +16.77% | 228B | |
| +14.63% | 177B |
SHIRE 
